Back to Explorer

Administrative Procedures for CLIA Categorization: Guidance for Industry and Food and Drug Administration Staff

FinalCenter for Devices and Radiological Health10/02/2017

Description

On February 28, 1992, the Department of Health and Human Services (DHHS) published laboratory standards regulations (57 FR 7002) implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. 263a). The implementing regulations are codified at 42 CFR Part 493. CLIA regulates laboratory testing and requires that clinical laboratories obtain a certificate before accepting materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or the impairment of, or assessment of the health of human beings. The type of CLIA certificate a laboratory obtains depends upon the complexity of the tests it performs. CLIA regulations describe the following three levels of test complexity: waived tests, moderate complexity tests, and high complexity tests. 42 CFR 493.5(a).

Scope & Applicability

Product Classes

2
IVD

Example 6: In vitro diagnostic for Candida species susceptibility

In Vitro Diagnostic

IVD device clinical studies conducted on de-identified specimens

Stakeholders

1
Manufacturer

Entity responsible for submitting NDINs

Regulatory Context

Attributes

5
High Complexity

complexity categorization for clinical laboratory devices

Moderate Complexity

complexity categorization for clinical laboratory devices

High complexity tests

One of the three levels of CLIA test complexity.

Moderate complexity tests

One of the three levels of CLIA test complexity.

Waived tests

One of the three levels of CLIA test complexity.

Related Warning Letters (1)

  • CGMP/QSR/Medical Devices/Misbranded

    Wello Inc.

    2023-11-14

See Also (8)

Administrative Procedures for CLIA Categorization: Guidance for Industry and Food and Drug Administration Staff | Guideline Explorer | BioRegHub